Key industry drivers include cost advantages in China, 100% FDI in India, and demand for injectable drugs in cancer research Key industry drivers include cost advantages in China, 100% FDI in India...

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a research license agreement with Catalent to evaluate certepetide, its iRGD cyclic peptide candidate, using Catalent's SMAR...

All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transa...

Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S's pending acquisition of Catalent, Inc. (Catalent), including expiry...

SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo...

SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo...

EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of contract drug manufacturer Catalent , according to a filing on the European Commission website on Monday.

Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug...

CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.

Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said on Monday.

Ghent, Belgium, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlan...

U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's controlling shareholder would acquire contract drug manufacturer Cata...

Catalent said on Friday it was unable to file its annual report with regulators on time as it requires additional time to complete "certain processes".

CTLT's solid segmental results led to an encouraging fiscal fourth-quarter performance, driving up share prices in after-hours trading.

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.